Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
Publication/Presentation Date
11-2024
Volume
144
Issue
1
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Article
COinS
